Breaking News on Global Pharmaceutical Technology & Manufacturing

3D pill printing firm Aprecia leases Forest Labs site as production hub

02-Mar-2015 - 3D drug printing firm Aprecia Pharmaceutical has leased an old Forest Labs facility sold following the firm’s $28bn takeover by Actavis last year .

Sosei, so good: Heptares' collaborations to continue post takeover

26-Feb-2015 - Sosei's takeover will not impact Heptares's antibody tech collaboration with Morphosys according to the UK membrane protein specialist.

Salix latest purchase by Valeant after Dendreon deal

26-Feb-2015 - Valeant has signed a $14.5bn deal to acquire GI drugmaker Salix days after agreeing to purchase Provenge-maker Dendreon.

Syringe reuse not clever: WHO advocates use of "smart" syringes to stop disease spread

23-Feb-2015 - ‘Smart’ syringes that can’t be reused should be the drug and vaccine delivery technology of choice for healthcare programmes according to the WHO, which says needle reuse is spreading deadly infectious diseases.

Drug delivery tech’s shares skyrocket as it helps Novo Nordisk clear Phase II hurdle

23-Feb-2015 - A potential Type 2 diabetes drug from Novo Nordisk has met the primary endpoint of a Phase II trial and shares of Emisphere Technology, which helped to formulate the oral version of semaglutide, jumped by as much as 70% on Friday.

Lupin plans to take on GSK’s Advair and Forest Labs’s Aerochamber in the US

18-Feb-2015 - Lupin will co-develop a rival to GSK’s Advair in the US and has licensed rights to an inhaled drug delivery tech competitor for Forest Labs’s Aerochamber.

Targeting stem cell cilia could prevent obesity and yield new cancer and arthritis drugs say researchers

17-Feb-2015 - Having shorter hair stops you becoming fat…at least it does if you are a stem cell say researchers who claim restricting the growth of hair-like cilia found on such cells could yield new treatments for obesity.

Suboxone sales down as opioid addiction drug market intensifies

12-Feb-2015 - Opioid addiction drug Suboxone lost market share in 2014 according to newly independent Indivior, whose management says it is not intimidated by increased competition.

Ex-Unigene execs who run Enteris add API contracting service to delivery tech licensing business

12-Feb-2015 - Enteris BioPharma has broadened its business beyond drug delivery tech licensing and launched a contract API manufacturing service.

One in the eye for Lucentis? Pfenex says Pfizer takeover will benefit Hospira pact

11-Feb-2015 - Pfenex expects its new Lucentis biosimilar partnership to benefit from Pfizer’s economic clout after the Hospira takeover completes.

Unilife upping device production as market opportunity offsets flat sales

10-Feb-2015 - Unilife Corporation has ramped up production of delivery devices as pharmas looks to differentiate injectable therapies from the competition.

update: WHO says tech like Nanopatch can help get vaccines to the people that need them

Vaxxas raises $20m for nanopatch vaccine trials

10-Feb-2015 - Vaccine patch firm Vaxxas has raised $20m (€17.7m) to fund clinical development of its pipeline of influenza, polio and bacterial infection vaccines.

GSK to consolidate vaccines R&D ahead of Novartis unit takeover

09-Feb-2015 - GSK will close a vaccine R&D lab in Montana and establish a centralised development hub as it prepares to takeover Novartis jabs unit.

Chinese researchers develop nanocarrier for pancreatic cancer drug

09-Feb-2015 - Researchers from the Oncology Department of Tianjin Medical University Cancer Hospital in China recently published a study in Advanced Functional Materials  announcing the creation of a new nano-carrier for pancreatic cancer treatments.

Water Street targets generic injectables sector with CMO buy

05-Feb-2015 - Water Street Healthcare Partners has bought US generic injectables contractor Custopharm.

Inhaled insulin: Sanofi alone as Big Pharma declines to revisit past

04-Feb-2015 - Pfizer, Lilly and Novo Nordisk will not be revisiting inhaled insulin opportunities despite the US launch and expected success of Sanofi and MannKind’s Afrezza.

Google picks Biogen Idec MS project for research partnership

29-Jan-2015 - Google and Biogen Idec are teaming up to crack multiple sclerosis, the latest crossover between pharma and the wearables world.


Ebola: which are the leading vaccine candidates?

27-Jan-2015 -'s interactive guide to the world's most promising Ebola vaccines.

Catalent to offer integrated services in Germany through softgel expansion

27-Jan-2015 - A coating and packaging expansion at a facility in Germany will feed the demand for end-to-end softgel services, Catalent Pharma Solutions says.

Pharma turning to injectable systems to protect biologics, says Unilife

22-Jan-2015 - Big Pharma firms like AbbVie are partnering with delivery device makers to guard against biosimilar competition according to Unilife CEO,  Alan Shortall.

Novozymes predicts half-life boost for pharma business, but lets long term rev forecast slide on oil prices

20-Jan-2015 - Novozymes finished 2014 with higher pharma revenues thanks in part to GSK's adoption of its albumin half-life extension technology, Veltis.

MannKind: Small step for delivery tech R&D after Afrezza's giant leap

19-Jan-2015 - MannKind’s development of new drugs with the delivery technology used in its inhalable insulin drug Afrezza will progress without founder Alfred Mann at the helm.

Capsugel buys ionic liquid tech IP to enhance lipid-based drug solubility

12-Jan-2015 - Capsugel has acquired a technology platform which uses ionic liquids to enhance the solubility of lipid-based drug delivery systems.

US pharmacy deals could cut costs of AbbVie and Gilead's HCV treatments

06-Jan-2015 - Gilead and AbbVie’s exclusive deals with payers CVS and Express Scripts could help cut the cost of the new class of treatments for America’s three million Hepatitis C sufferers.

India SRF buys DuPont's Dymel business and plans pharma plant

05-Jan-2015 - India SRF will set up a pharma-grade inhaler propellant manufacturing plant in India with tech and knowhow acquired from US chemical company DuPont.


Third time's a charm: Pfizer to buy Hospira for $17bn
breaking news

Third time's a charm: Pfizer to buy Hospira for $17bn

Pfizer has entered into a definitive merger agreement to buy Hospira for $17bn.

Vertellus buys antiretroviral API reagent plant from Dow

Vertellus buys antiretroviral API reagent plant from Dow

Specialty chemicals firm Vertellus will continue to supply antiretroviral drugmakers sodium borohydride following its takeover of a...

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm: profits fall on higher costs, an idle plant and lower Qsymia sales

ScinoPharm was hurt by weak US demand for the weight loss pill Qsymia, higher raw material prices...

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Analyst: Pfizer's withdrawal from Repligen deal "not smart" amid growing Big Pharma interest in SMA

Pfizer must act fast to convince investors it can compete with Roche and Biogen Idec for a...

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

MUGAS-funded Tamiflu analysis included fewer studies than Cochrane review

Researchers claiming Tamiflu cuts flu symptom duration and hospitalisations analysed less than half as many studies as...

Key Industry Events


Access all events listing

Our events, Shows & Conferences...